Literature DB >> 3357721

Is histamine responsible for the symptoms of rhinovirus colds? A look at the inflammatory mediators following infection.

R M Naclerio1, D Proud, A Kagey-Sobotka, L M Lichtenstein, J O Hendley, J M Gwaltney.   

Abstract

In an attempt to identify inflammatory mediators that may contribute to rhinorrhea, nasal congestion and other cold symptoms, we recruited 40 healthy young adults (median age, 20) for provocative rhinovirus challenge. Mediators measured included histamine, kinins and enzymes with arginine esterase activity. Volunteers were inoculated with rhinovirus or a sham inoculum. Nasal secretions for viral culture were obtained daily, and volunteers were deemed infected if they shed virus or had a 4-fold or greater increase in serum antibody titer. The virus-infected group was subdivided using the Jackson criteria into an ill or non-ill group; each group was compared to the control group. Of the 27 virus-inoculated subjects, 25 had positive cultures for the challenge virus, and 15 became ill. None of the controls had a positive culture. All variables measured--except histamine--grew stronger in direct relationship with the symptoms as the cold increased in severity. In the infected-ill group, the mean kinin level increased more than 10-fold over baseline. The kinin level remained relatively unchanged in the control and non-ill groups. Similar results were found for levels of albumin and enzymes with arginine esterase activity. Histamine levels remained constant in both the infected-ill and non-ill groups, which suggests that mast cells and basophils do not participate in the pathophysiology of rhinovirus infections and that antihistamines should be ineffective in treating rhinovirus colds. Since volunteers who developed cold symptoms exhibited a notable increase in kinin, a potent inflammatory mediator, we recommend further study of a kinin antagonist in reducing nasal symptoms.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3357721     DOI: 10.1097/00006454-198803000-00031

Source DB:  PubMed          Journal:  Pediatr Infect Dis J        ISSN: 0891-3668            Impact factor:   2.129


  11 in total

Review 1.  Cold comfort for the catarrhal child.

Authors:  D Isaacs
Journal:  Arch Dis Child       Date:  1990-12       Impact factor: 3.791

Review 2.  Problems and prospects of developing effective therapy for common cold viruses.

Authors:  S L Johnston
Journal:  Trends Microbiol       Date:  1997-02       Impact factor: 17.079

Review 3.  Nasal cytokines as mediators of illness during the common cold.

Authors:  William J Doyle; David P Skoner; Deborah Gentile
Journal:  Curr Allergy Asthma Rep       Date:  2005-05       Impact factor: 4.806

4.  Adaptation of an ICAM-1-tropic enterovirus to the mouse respiratory tract.

Authors:  Eric S Wang; Elena Dobrikova; Christian Goetz; Andrew T Dufresne; Matthias Gromeier
Journal:  J Virol       Date:  2011-03-30       Impact factor: 5.103

Review 5.  Mast Cell Responses to Viruses and Pathogen Products.

Authors:  Jean S Marshall; Liliana Portales-Cervantes; Edwin Leong
Journal:  Int J Mol Sci       Date:  2019-08-30       Impact factor: 5.923

Review 6.  Cromolyns: treatment for the common cold.

Authors:  S L Johnston
Journal:  Clin Exp Allergy       Date:  1996-09       Impact factor: 5.018

Review 7.  The common cold and asthma.

Authors:  N Mygind; J M Gwaltney; B Winther; J O Hendley
Journal:  Allergy       Date:  1999       Impact factor: 13.146

Review 8.  The common cold.

Authors:  G L Kirkpatrick
Journal:  Prim Care       Date:  1996-12       Impact factor: 2.907

9.  Variant effect of first- and second-generation antihistamines as clues to their mechanism of action on the sneeze reflex in the common cold.

Authors:  P S Muether; J M Gwaltney
Journal:  Clin Infect Dis       Date:  2001-10-04       Impact factor: 9.079

10.  Vascular endothelial growth factor induction by rhinovirus infection.

Authors:  Dinesha De Silva; Hayat Dagher; Reena Ghildyal; Mandy Lindsay; Xun Li; Nicholas J Freezer; John W Wilson; Philip G Bardin
Journal:  J Med Virol       Date:  2006-05       Impact factor: 2.327

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.